- Investing Ideas
- Canadian Pharmaceuticals & Biotech Healthy potentially undervalued
Canadian Pharmaceuticals & Biotech Healthy potentially undervalued
Results
8
Companies which are potentially undervalued and in an acceptable financial position.
8 companies
High Tide
Market Cap: CA$268.9m
Engages in the cannabis retail business in Canada, the United States, and internationally.
HITI
CA$3.11
7D
2.0%
1Y
-4.9%
Decibel Cannabis
Market Cap: CA$63.5m
An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.
DB
CA$0.10
7D
-8.7%
1Y
5.0%
Aurora Cannabis
Market Cap: CA$227.3m
Engages in the production, distribution, and sale of cannabis products in Canada and internationally.
ACB
CA$3.78
7D
0.5%
1Y
-45.0%
Curaleaf Holdings
Market Cap: CA$3.5b
Engages in the retail and wholesale of cannabis products in the United States and internationally.
CURA
CA$13.52
7D
-2.5%
1Y
178.2%
Green Thumb Industries
Market Cap: CA$2.2b
Manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States.
GTII
CA$9.91
7D
-6.1%
1Y
24.0%
Medexus Pharmaceuticals
Market Cap: CA$160.8m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$5.04
7D
-1.8%
1Y
90.2%
Verano Holdings
Market Cap: CA$579.4m
Engages in the cannabis business in the United States.
VRNO
CA$7.95
7D
-2.8%
1Y
101.3%
Organigram Global
Market Cap: CA$183.0m
Engages in the production and sale of cannabis and cannabis-derived products in Canada.
OGI
CA$1.32
7D
5.6%
1Y
-37.4%